Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

© Synapse Social LLC, 2026

Política de privacidad

Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure | Synapse

May 2, 2024Open Access

Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to have benefits when used in patients with heart failure. The comparative outcomes of SGLT2 inhibitors relative to each other has not been well defined and may impact medication selection.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Modzelewski et al. (Thu,) studied this question.

synapsesocial.com/papers/68e6bbd2b6db64358763c93e https://doi.org/https://doi.org/10.1001/jamanetworkopen.2024.9305

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo